Skip to main content

ORIGINAL RESEARCH article

Front. Genet.
Sec. Computational Genomics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1522484

Exploring Prognosis and Therapeutic Strategies for HBV-HCC Patients Based on Disulfidptosis-Related Genes

Provisionally accepted
Chuankuo Zhang Chuankuo Zhang Xing Zhang Xing Zhang *WenJun Yang WenJun Yang *
  • First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

The final, formatted version of the article will be published soon.

    Background: Hepatocellular carcinoma (HCC) accounts for over 80% of primary liver cancers and is the third leading cause of cancer-related deaths worldwide. Hepatitis B virus (HBV) infection is the primary etiological factor. Disulfidptosis is a newly discovered form of regulated cell death. This study aims to develop a novel HBV-HCC prognostic signature related to disulfidptosis and explore potential therapeutic approaches through risk stratification based on disulfidptosis.Methods: Transcriptomic data from HBV-HCC patients were analyzed to identify BHDRGsdisulfidptosis-related genes (BHDRGs). A prognostic model was established and validated using machine learning, with internal datasets and external datasets for verification. We then performed immune cell infiltration analysis, tumor microenvironment (TME) analysis, and immunotherapy-related analysis based on the prognostic signature.10 paired HBC-HCC specimens was used to verify the expression of BHDRGs through immunohistochemistry staining.Besides, RT-qPCR and immunohistochemistry were conducted.Results: A prognostic model was constructed using five genes (DLAT, STC2, POF1B, S100A9, and CPS1). A corresponding prognostic nomogram was developed based on riskScores, age,stage.Stratification by median risk score revealed a significant correlation between the prognostic signature and TME, tumor immune cell infiltration, immunotherapy efficacy, and drug sensitivity.The results of the immunohistochemical experiments indicate that DLAT expression is higher in tumor tissues compared to adjacent tissues.DLAT expression is higher in HBV-HCC tumor tissues compared to normal tissues.This study stratifies HBV-HCC patients into distinct subgroups based on BHDRGs, establishing a prognostic model with significant implications for prognosis assessment, TME remodeling, and personalized therapy in HBV-HCC patients.

    Keywords: disulfidptosis1, Hepatitis B virus2, hepatocellular carcinoma3, immunotherapy4, prognosis model5

    Received: 04 Nov 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Zhang, Zhang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xing Zhang, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
    WenJun Yang, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.